Skip to main content
Premium Trial:

Request an Annual Quote

Biomatics Capital Closes $200M Fund, Plans Genomics, Digital Health Investments

NEW YORK (GenomeWeb) – Venture capital firm Biomatics Capital Partners said today that it has closed an initiatory fund of $200 million, surpassing an initial target of $150 million.

The fund is being led by Cofounders and Managing Directors Boris Nikolic and Julie Sunderland. Nikolic previously served as chief advisor for science and technology to Bill Gates and Sunderland was director of program related investments for the Bill & Melinda Gates Foundation.

The money Biomatics has raised will be used to invest in the areas of genomics, digital health, and data-driven health care technologies. The firm estimated that it will invest in 15 to 20 companies overall, acting as Series A lead investor in most of the deals. Initial investments would typically range from $5 million to $10 million, with up to $20 million over the life of the investment, the company added.

The firm's current portfolio of investments includes cancer early detection firm Grail, Omniome, and Twist Bioscience, among others.

"It’s our goal to seek out radically innovative solutions — the outliers," Sunderland said in a statement. "By combining the best of science with sound investment practices, we are looking to create extraordinary financial value for our investors and a pathway to better patient outcomes."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.